Zymeworks Inc. (ZYME) EPS Estimated At $-0.62; AP MOELLER MAERS B (AMKBF) Sellers Decreased By 0.46% Their Shorts

January 17, 2018 - By wolcottdaily

AP MOELLER MAERS B (OTCMKTS:AMKBF) had a decrease of 0.46% in short interest. AMKBF’s SI was 21,500 shares in January as released by FINRA. Its down 0.46% from 21,600 shares previously. With 100 avg volume, 215 days are for AP MOELLER MAERS B (OTCMKTS:AMKBF)’s short sellers to cover AMKBF’s short positions. It closed at $1846.1 lastly. It is down 0.00% since January 17, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts expect Zymeworks Inc. (NYSE:ZYME) to report $-0.62 EPS on February, 14.After having $-0.65 EPS previously, Zymeworks Inc.’s analysts see -4.62% EPS growth. The stock increased 2.33% or $0.23 during the last trading session, reaching $10.09. About 2,513 shares traded. Zymeworks Inc. (NYSE:ZYME) has 0.00% since January 17, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 4 analysts covering Zymeworks (NYSE:ZYME), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Zymeworks had 4 analyst reports since May 23, 2017 according to SRatingsIntel. The firm has “Outperform” rating given on Tuesday, May 23 by Wells Fargo. As per Tuesday, May 23, the company rating was initiated by Canaccord Genuity. The rating was initiated by Citigroup on Tuesday, May 23 with “Buy”. The firm has “Overweight” rating by Barclays Capital given on Tuesday, May 23.

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company has market cap of $254.06 million. The companyÂ’s lead product candidate include ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast, gastric, and ovarian cancers. It currently has negative earnings. It is also developing ZW33, a bispecific anti-human epidermal growth factor receptor 2 antibody-drug conjugate that is in preclinical development stage for the treatment of breast and ovarian cancers.

A.P. Møller – Mærsk A/S operates as a shipping firm worldwide. The company has market cap of $37.72 billion. The companyÂ’s Maersk Line segment provides container shipping services. It currently has negative earnings. The Company’s APM Terminals segment engages in container terminal activities and inland transportation services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: